hemostatic agent used for the treatment and prevention of excessive blood loss. In this pharmacological group is Tranexam domestic preparation, in the operating instructions for bleeding tablets marked their efficiency and performance. This medicine may be given to pregnant women.
Composition and indications for use
Tranexam is available in tablet and injectable forms. The active component of the drug is tranexamic acid.
The tablets are enteric film coating consisting of hypromellose, talc, titanium dioxide and macrogol. The composition contains the active substance core, present in an amount of 0.25 or 0.5 g, and auxiliaries:
- giproloza;
- microcellulose;
- calcium stearate;
- colloidal silica;
- talc;
- sodium salt of carboxymethyl starch.
The drug has a local and systemic effect, lengthens the thrombin time, helps to restore hemostasis by increasing blood viscosity. Its pharmacological properties:
- antifibrinolytic;
- hemostatic;
- anti-inflammatory;
- antiallergic;
- analgesic;
- antineoplastic.
Tranexamic acid inhibits the formation of plasmin, a fibrinolytic enzyme, inhibits its activity, inhibits the production of kinins, and other physiologically active peptides. It is well distributed in the body, overcoming the blood-brain barrier, it is found in seminal fluid may accumulate in the tissues in renal dysfunction.
The medicine is used for the elimination and prevention of blood loss resulting from excessive fibrinolysis. He was appointed in hemophilia, thrombocytopenia, leukemia, aplastic anemia, local bleeding (pulmonary, nasal, gastrointestinal etc.), complications during surgery, hemorrhage due to use fibrinolytic agents. Also, the medicament is used in various allergic manifestations, including hereditary angioneurotic edema, and as anti-inflammatory agent for tonsillitis, pharyngitis, laryngitis.
Applicable Tranexam and uterine bleeding caused by polyps, endometriosis, hyperplasia, leiomyoma, hormonal imbalance, oral contraceptives, inflammation, aborted fetuses by conducting a survey cavity uterus. It helps with menorrhagia, reducing the duration of menstruation and reducing the amount of bleeding.
The tablets should not be taken if you are hypersensitive, thrombosis, severe renal failure, myocardial infarction, subarachnoid hemorrhage, Impaired color perception, convulsive phenomena.
With its use caution when propensity to thrombosis, DIC, gross hematuria and combined with the combined contraceptives. Clinical experience in the treatment of menorrhagia in women younger than 16 years is limited.
Despite the fact that the drug passes the placental barrier and is excreted in breast milk, if necessary, a doctor can prescribe it during pregnancy and the postpartum period.
Means advantageously has symptomatic effects. To eliminate the disease that caused bleeding, sometimes it requires appropriate treatment.
How and how much to drink
Tranexam bleedings taken in consultation with your doctor. Drink the medicine can be, regardless of the meal. The tablets are small in size and enteric coating, they can easily be swallowed whole, chewed or dissolve them should not be.
Dosage prescribed individually depending on the available evidence. The drug is not used for the treatment of children, the age limit - 12 years. The standard daily dose for adults is 3-4 g It must be taken for 2-3 sunset at regular intervals.
If necessary, first intravenously administered tranexamic acid and then converted to the patient oral preparation.
A single dose can be determined by calculation from 15-25 mg / kg.
increase the amount of drug if necessary. During the day it is impossible to use more than 8 tablets Traneksama 500 mg. In the case of missing the reception of the medicament to double the next dose should not.
Information about those patients who drank Tranexam during treatment with anticoagulants, inadequate. Simultaneous use of medicines with others hemostatic increases the risk of thrombosis and the development of other side effects:
- dizziness;
- asthenia;
- headache;
- hypotension;
- dyspepsia;
- tachycardia;
- impaired color perception;
- allergic reactions in the form of wearable rash, redness, itching, swelling.
When adverse reactions pills should be discontinued.
To prevent accumulation of the drug to patients with mild renal insufficiency should be minimal to reduce the dosage and frequency depending on the reception level of creatinine.
When the drug is given uterine bleeding gynecologist. Pregnant it is prescribed in case of an emergency and provide treatment under strict medical supervision. Most often, it is recommended to drink 1 tablet of 250 mg or 500 mg 3 times a day. Nursing mothers should suspend breastfeeding.
Menorrhagia properly start taking means in the first day of menstruation. Proactively taking it can delay the onset of menses for 1-2 days, but experts strongly recommend to refrain from such practices.
How quickly stops bleeding
When taken orally, the drug in the systemic circulation adjudged not more than 50% of the dose, and the maximum concentration of active ingredient is achieved plasma 3 hours. Efficiency and speed of the drug depends on the cause hemorrhage, the individual and other factors. Tranexam considered one of the best hemostatic, but should not expect immediate effect. Thanks to its action stops the bleeding gradually, on average, it takes between 3 to 7 days. The process may be delayed.
Medication does not always help. He can not give the desired result or more to reduce blood loss and not completely stop it. However, unauthorized or increase the dosage or extend the cure should not be.
How many days you can drink
The duration of the drug is determined by the physician on an individual basis based on the available evidence. For example, menorrhagia treatment should not exceed 4 days with recurrent nasal bleedings of 1 week, in the postoperative period is extended until complete disappearance hemorrhagic manifestations (12-14 days), and for the prevention of exacerbations with hereditary angioedema edema may be taken permanently basis.
Indications for early discontinuation is an overdose and the development of adverse symptoms.
